

The world's leading CRO

Powered by Healthcare Intelligence

ICON is the world's largest pure-play clinical research organisation. From molecule to medicine, we advance clinical research by providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government, and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. ICON offers the most comprehensive suite of integrated clinical development services in the industry. We've designed fully customisable solutions to help our customers achieve their goals across a seamless delivery model, spanning their product's entire lifecycle.

Our focus is on delivering Healthcare Intelligence to customers to address the full spectrum of clinical development challenges, not just point-of-service delivery. The synthesis of our experience, expertise, best practices, technology and data provides patient centric processes, commercially optimised for global success, and is driving transformation of trials to improve R&D ROI. ICON has established relationships with a majority of the world's top pharmaceutical and biotech companies, offering:

Globally scaled expertise and solutions for all customers and patients. ICON is:

- World leader in Functional Service Provision (FSP)
- Global number 2 in full-service Ph 2/3 Clinical Research
- Global number 2 in Early Phase Clinical Research
- Global number 3 in Late Phase & RWE
- Global number 4 in Central & Speciality Laboratory Services

Clinical focus: no ownership from parent organisation and no distractions from 'near adjacencies', means we are completely committed to customers' clinical development programmes.


Flexible partnership models and governance structures ensure transparent communications. Regardless of the size of your organisation or your project, we work your way.

Strategy-driven delivery: At ICON, we know that clinical research now requires a more comprehensive, strategy-driven delivery. Our approach is to proactively guide clients towards the most effective, efficient solution across all modalities of research.

We commence client engagements with a strategic consultation, delivered by our team of over 700 consultants, to identify custom solutions, eliminate process white space and identify efficiencies and savings. This delivers across three areas:

- Robust asset development consulting for a deeper understanding of development pathways, asset acquisition/transfer options and access to scientific expertise across disciplines for ad hoc support.
- A network of international experts delivering superior regulatory and quality assurance strategies, submissions, and support to expedite drug and medical device development and manage ongoing global compliance.
- Integrated solutions to demonstrate the value of products and support global brand success from dedicated real-world evidence, pricing, market access, reimbursement, health economics, and medical communications experts.

This consultative-led approach, the breadth of our capabilities and advanced digital and data capabilities enables us to deliver seamless, integrated services.





Decentralised clinical trial: Clinical research should engage with patients wherever they are. ICON has all the service components to deliver DCTs and the experience and expertise to provide integrated, customised solutions. Our integrated decentralised clinical trial solutions can help customers to achieve better outcomes, while maximising recruitment and retention of diverse patient populations.

Site and patient recruitment: Our site networks, patient recruitment expertise, in-home services and site resourcing services unlock access to millions of patients. Patients are at the heart of everything we do at ICON. We provide the most comprehensive and connected patient journeys across the largest and most diverse patient populations. ICON streamlines the clinical trial process, accelerating study startup, and ensuring patient recruitment and retention meet or exceed targets. ICON offers customers enhanced access to a larger global pool of more diverse patients through its global site network (Accellacare), specialised oncology network (Oncacare), a paediatric site network, in-home services and a network of five Phase I clinical research units across the United States and Europe.

Speed to market: An extensive services portfolio, digital and technology capabilities, combined with flexible delivery and models allow us to reduce development time and costs.

Quality: The quality of our work is vital to our mission of bringing better medications to patients around the world. We are committed to maintaining, supporting, checking, and improving our quality systems to exceed the quality standards demanded by our clients, patients and regulatory authorities. ICON's Quality Management System (QMS) comprises our mechanisms for ensuring that all our services are performed to the highest ethical standards, conform to all relevant regulatory requirements and satisfy contractual obligations.

Emerging therapies: ICON offers deep experience in the unique challenges of developing emerging treatments such as immuno-oncology and other cell and gene therapies, with several approved treatments already on the market.

Advanced digital and data capabilities: Innovation at ICON is focused on the factors that are critical to our clients. Investing heavily in AI, machine learning and RPA capabilities, our portfolio of digital solutions and platforms are specifically developed for the needs for clinical research. Our enterprise clinical informatics framework ingests, integrates and interrogates the full spectrum of data sources, and assets for rich, real-time data-visualisation and actionable insights to significantly enhance the efficiency and productivity of clients' development programmes.

Data insights can include experiential data paired with external data, benchmark data on different models of research, predictive algorithms and continuous performance evaluation, whilst tokenisation of data extends reusability.

[ICONplc.com](https://www.iconplc.com)

ICON is driving transformation of trials to improve R&D ROI and support a future landscape of many more trials delivered in shorter timeframes, but conversely of greater operational and scientific complexity. We strategically and proactively solve today's challenges without losing sight of their impact tomorrow.



Government



Biotech



Pharma



Medical Device



Public Health



Consumer Health